GLP.exe - a safe and effective treatment for Type 2 Diabetes Mellitus
Several treatment options for Type 2 Diabetes Mellitus
have been developed in recent years significantly improving the patients' insulin level.
Hence, the diagnosis of Type 2 Diabetes Mellitus is no longer a death sentence.
are expensive, require fine tuning and daily shots.
Moreover, they have severe side-effects, causing patients to skip doses.
“Many patients don’t want to use insulin. They don’t want
to do finger sticks and they’re afraid of hypoglycemia.”
“To fight the global Diabetes pandemic, we would ideally have an accessible cost-effective
easily-compliant intervention that has high clinical efficacy and that is free of adverse side
Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York
Our therapeutic agent is a probiotic secreting incretin
mimetics placed in the patients intestine by oral administration of capsules. GLP-1 and Exendin-4,
main actors, cause an increase in insulin secretion, if the cell has already taken up sugar.
This enables an easier therapy where a regular intake of
medicals is not required.
Improved cell penetrating peptides with the use of
artificial intelligence allow for an efficient and safe transport of our effectors into the
is our highest
Therefore, we developed a novel, Cas3 based kill-switch
mechanism. The flexible system uses three regulators inspired by the human intestines: temperature,
availability of fatty acids in form of Acyl CoA and N-Acetyl-Glucosamin.
If the conditions of our regulatory system are no longer met, Cas3 will be degrading all genetic
An in depth E. coli Nissle characterization
Despite the fact that E. coli Nissle is an already
approved probiotic, it's surprisingly badly characterized.
Hence, we provide the first metabolic model of E. coli Nissle and optimize it's growth for various
growth media. Furthermore, we predicted the interaction and competition of E. coli Nissle with
common competitors for various fluxes in the gut.
Finally, we carried out a series of RNA-Seq experiments to assess the adaptions and reactions of E.
Nissle to aerobic, as well as anaerobic occurring stress factors.
Bringing it all together
Our work lays the foundation for an innovative, unprecedented approach
to treat Type 2 Diabetes Mellitus.